TSLA
Tesla
-- 230.580 NVDA
NVIDIA
-- 108.760 PLTR
Palantir
-- 78.050 AAPL
Apple
-- 220.840 GRRR
Gorilla Technology
-- 26.990 
NEWS
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents (NASDAQ: CTSO) and Converge Biotech have announced a strategic partnership to expand their market reach in India's sepsis and critical care markets. CytoSorbents' flagship product, CytoSorb, a blood purification technology that reduces cytokine storm and inflammatory toxins, will be distributed through Converge Biotech's extensive critical care sales network. CytoSorb, currently used in 76 countries with over 250,000 treatments administered, treats conditions like sepsis, septic shock, lung failure, acute liver disease, and trauma. The partnership aims to improve patient outcomes across Indian hospitals and ICUs by combining CytoSorbents' innovative technology with Converge's established critical care presence.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment